#United States #New York #biotechnology #Rigel Pharmaceuticals #RBC Conference

Rigel Pharmaceuticals Set to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Rigel Pharmaceuticals, Inc., a biotechnology company publicly traded on Nasdaq under the symbol RIGL, is poised to take center stage at the highly anticipated 2026 RBC Capital Markets Global Healthcare Conference. This event, scheduled for May 19, 2026, at 9:30 a.m. ET, will unfold in New York City. Dean Schorno, the Chief Financial Officer of Rigel, will deliver an overview of the company's innovative endeavors in treating hematologic disorders and cancer.

Rigel, founded in 1996 and located in South San Francisco, California, has established itself as a significant player in the biotechnology sector, focusing on developing therapies aimed at improving patient outcomes in various challenging medical conditions. This upcoming presentation is part of the company's effort to showcase its advancements and ongoing projects to investors and stakeholders within the healthcare community.

To access the live presentation, investors and interested parties are encouraged to visit Rigel's Investor Relations section on their website. Here, attendees can participate in the live webcast as well as find any archived recordings post-event. It is recommended that connections to Rigel's site are established ahead of time to facilitate any necessary software downloads required for viewing the event.

Rigel is dedicated to discovering and delivering novel treatments, particularly in hematology and oncology, areas that are crucial for many patients worldwide. As part of its commitment to transparency and engagement with the investment community, the company regularly participates in conferences and events like the RBC Capital Markets Healthcare Conference.

The 2026 conference marks a significant opportunity for Rigel to highlight its pipeline of potential therapies and offer insights into its current market strategies. Investors viewing this presentation can expect comprehensive information about Rigel's existing products and upcoming innovations designed to elevate patient care and improve health outcomes.

Through its participations in such leading industry conferences, Rigel Pharmaceuticals continues to reinforce its position at the forefront of biotechnology, addressing critical health challenges through cutting-edge research and development initiatives. Stakeholders can stay informed about Rigel's progress and updates by regularly visiting their official website or following their investor communications.

With the growing recognition of the company's potential in developing targeted therapies for unmet medical needs, the upcoming presentation at RBC should not be missed. As Rigel Pharmaceuticals steps into the spotlight, the healthcare community and investors alike will be keenly observing the insights and developments shared during this pivotal event.